Skip to main content

Table 5 Comparison of all lupus nephritis treatments for bone marrow toxicity (cytopenia including leucopenia)

From: Comparative effectiveness of immunosuppressive drugs and corticosteroids for lupus nephritis: a systematic review and network meta-analysis

Treatment Reference OR (95 % CrI) RR (95 % CrI) RD % (95 % Crl)
CYC SD MMF 2.16 (1.14, 4.03) 1.99 (1.13, 3.37) 0.07 (0.01, 0.16)
AZA SD   2.42 (1.01, 7.07) 2.19 (1.01, 5.06) 0.09 (0.00, 0.27)
CYC LD   5.31 (1.26, 24.65) 4.03 (1.23, 10.11) 0.22 (0.02, 0.56)
CYC HD   5.36 (1.95, 18.08) 4.06 (1.81, 8.96) 0.22 (0.07, 0.48)
RTX + MMF SD   3.50 (0.61, 23.14) 2.95 (0.63, 9.43) 0.14 (−0.03, 0.56)
AZA SD CYC SD 1.11 (0.39, 4.03) 1.09 (0.44, 3.07) 0.01 (−0.11, 0.22)
CYC LD   2.45 (0.51, 13.07) 2.01 (0.56, 5.91) 0.15 (−0.08, 0.50)
CYC HD   2.47 (0.77, 9.99) 2.03 (0.80, 5.38) 0.15 (−0.04, 0.43)
RTX + MMF SD   1.63 (0.26, 11.77) 1.49 (0.30, 5.31) 0.07 (−0.13, 0.49)
CYC LD AZA SD 2.16 (0.42, 10.83) 1.80 (0.49, 5.39) 0.13 (−0.12, 0.47)
CYC HD   2.20 (0.56, 8.96) 1.83 (0.65, 5.16) 0.13 (−0.10, 0.40)
RTX + MMF SD   1.43 (0.18, 11.42) 1.33 (0.23, 5.33) 0.05 (−0.21, 0.48)
CYC HD CYC LD 1.01 (0.29, 3.75) 1.01 (0.46, 2.74) 0.00 (−0.28, 0.24)
RTX + MMF SD   0.66 (0.06, 7.15) 0.74 (0.12, 3.78) −0.07 (−0.48, 0.40)
RTX + MMF SD CYC HD 0.65 (0.08, 5.36) 0.73 (0.13, 2.81) −0.08 (−0.41, 0.37)
Random-effects model Residual deviance   31.43 vs. 33 data points  
  Deviance information criteria   165.076  
Fixed-effects model Residual deviance   38.78 vs. 33 data points  
  Deviance information criteria   167.984  
  1. Based on 16 RCTs with 2257 patients: 15 two-arm trials and one three-arm trial
  2. Significant odds ratios are in italics
  3. For absolute rates for events used for calculation of risk difference, please see Appendix 6
  4. OR odds ratio, RR relative risk, RD risk difference, CrI credible interval, HD high dose, LD low dose; when not specified, it indicates standard dose, CYC cyclophosphamide, MMF mycophenolate mofetil, CSA cyclosporine, TAC tacrolimus, LEF leflunomide, PRED prednisone, prednisolone or methylprednisolone, AZA azathioprine, RTX rituximab
  5. MMF-AZA, MMF followed by AZA
  6. RTX + MMF, RTX combined with MMF
  7. Estimates for LEF HD were obtained from data from only one study and were therefore imprecise
  8. The odds ratios were transformed to relative risk (RR) and risk difference was done to allow ease for interpretation for clinicians and patients